NIAGARA: Durvalumab plus chemo improves EFS and OS in cisplatin-eligible MIBC

Perioperative durvalumab plus neoadjuvant chemotherapy followed by radical cystectomy and adjuvant chemotherapy demonstrated significant event-free survival and overall survival benefits in cisplatin-eligible muscle-invasive bladder cancer patients, according to the NIAGARA study presented at the 2024 ESMO Congress.